Ingredients Insider - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ingredients Insider

Asymmetric Synthesis Continues to Advance

September 2, 2014

Pharmaceutical Technology

A survey of the recent literature reveals numerous advances in asymmetric chemocatalysis.

Risk Reduction Top Driver for Biopharmaceutical Raw Material Development

August 2, 2014

Pharmaceutical Technology

Customers are looking to reduce risk, increase performance, and optimize productivity.

The Mainstreaming of Continuous Flow API Synthesis

July 2, 2014

Pharmaceutical Technology

The pharma industry is moving toward commercial-scale continuous processes for small-molecule API manufacturing.

Seeking Alternative Catalyst Solutions

June 2, 2014

Pharmaceutical Technology

Transition metal-containing catalysts are widely used in organic synthesis, but many are based on expensive, rare metals. Researchers are seeking more sustainable alternatives.

Scientific Advances in Cocrystals are Offset by Regulatory Uncertainty

May 2, 2014

Pharmaceutical Technology

Drug developers are taking a wait-and-see approach to the use of cocrystals.

Appropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs

April 2, 2014

Pharmaceutical Technology

Increasing potency and growing interest in antibody-drug conjugates are creating challenges for manufacturers of HPAPIs.

Synthetic Biology: The Next Frontier in Chiral Chemistry for API Synthesis

March 2, 2014

Pharmaceutical Technology

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.

A Look Ahead for Custom Manufacturing and Pharma

January 2, 2014

Pharmaceutical Technology

Emerging markets are an engine for growth in the custom-manufacturing and pharma markets.

Tracking Innovation in New Molecular Entities of 2013

December 2, 2013

Pharmaceutical Technology

A review of this year's crop of the new molecular entities and new biologics license applications approved by FDA thus far in 2013.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here